Screening-based approaches to identify small molecules that inhibit protein–protein interactions

Sehee Choi, Kang-Yell Choi

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: Protein–protein interactions (PPIs) are very attractive targets for drug development as they play important roles in regulating many aspects of pathophysiologies. It has recently been revealed that the functionally important region of most PPIs is small enough to be modulated by small molecules. Thus, many studies in this field have achieved amazing progress, together with diverse and advanced screening technologies. Areas covered: This article presents screening technologies to identify small molecule inhibitors of PPIs in addition to discussing the suitability of PPIs as molecular targets. The phases in the processes of selecting compounds are discussed and appropriate steps are proposed, including methodologies to test binding affinity, kinetics, structural analysis, and cellular function. Expert opinion: Targeting PPIs is still a challenging approach in drug development and relatively few small molecules have reached clinical development. Potential candidates should be assessed and optimized by properly using the multiple assay systems to develop ideal small molecule drugs. Although there remain some barriers to be overcome, small molecule inhibitors of PPIs are fascinating and first-in-class as therapeutic agents to treat various diseases.

Original languageEnglish
Pages (from-to)293-303
Number of pages11
JournalExpert Opinion on Drug Discovery
Volume12
Issue number3
DOIs
Publication statusPublished - 2017 Mar 4

Fingerprint

Pharmaceutical Preparations
Technology
Expert Testimony
Therapeutics
isofenphos

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Cite this

@article{8c588338c69c44e9a0259f9b2de042df,
title = "Screening-based approaches to identify small molecules that inhibit protein–protein interactions",
abstract = "Introduction: Protein–protein interactions (PPIs) are very attractive targets for drug development as they play important roles in regulating many aspects of pathophysiologies. It has recently been revealed that the functionally important region of most PPIs is small enough to be modulated by small molecules. Thus, many studies in this field have achieved amazing progress, together with diverse and advanced screening technologies. Areas covered: This article presents screening technologies to identify small molecule inhibitors of PPIs in addition to discussing the suitability of PPIs as molecular targets. The phases in the processes of selecting compounds are discussed and appropriate steps are proposed, including methodologies to test binding affinity, kinetics, structural analysis, and cellular function. Expert opinion: Targeting PPIs is still a challenging approach in drug development and relatively few small molecules have reached clinical development. Potential candidates should be assessed and optimized by properly using the multiple assay systems to develop ideal small molecule drugs. Although there remain some barriers to be overcome, small molecule inhibitors of PPIs are fascinating and first-in-class as therapeutic agents to treat various diseases.",
author = "Sehee Choi and Kang-Yell Choi",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/17460441.2017.1280456",
language = "English",
volume = "12",
pages = "293--303",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "3",

}

Screening-based approaches to identify small molecules that inhibit protein–protein interactions. / Choi, Sehee; Choi, Kang-Yell.

In: Expert Opinion on Drug Discovery, Vol. 12, No. 3, 04.03.2017, p. 293-303.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Screening-based approaches to identify small molecules that inhibit protein–protein interactions

AU - Choi, Sehee

AU - Choi, Kang-Yell

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Protein–protein interactions (PPIs) are very attractive targets for drug development as they play important roles in regulating many aspects of pathophysiologies. It has recently been revealed that the functionally important region of most PPIs is small enough to be modulated by small molecules. Thus, many studies in this field have achieved amazing progress, together with diverse and advanced screening technologies. Areas covered: This article presents screening technologies to identify small molecule inhibitors of PPIs in addition to discussing the suitability of PPIs as molecular targets. The phases in the processes of selecting compounds are discussed and appropriate steps are proposed, including methodologies to test binding affinity, kinetics, structural analysis, and cellular function. Expert opinion: Targeting PPIs is still a challenging approach in drug development and relatively few small molecules have reached clinical development. Potential candidates should be assessed and optimized by properly using the multiple assay systems to develop ideal small molecule drugs. Although there remain some barriers to be overcome, small molecule inhibitors of PPIs are fascinating and first-in-class as therapeutic agents to treat various diseases.

AB - Introduction: Protein–protein interactions (PPIs) are very attractive targets for drug development as they play important roles in regulating many aspects of pathophysiologies. It has recently been revealed that the functionally important region of most PPIs is small enough to be modulated by small molecules. Thus, many studies in this field have achieved amazing progress, together with diverse and advanced screening technologies. Areas covered: This article presents screening technologies to identify small molecule inhibitors of PPIs in addition to discussing the suitability of PPIs as molecular targets. The phases in the processes of selecting compounds are discussed and appropriate steps are proposed, including methodologies to test binding affinity, kinetics, structural analysis, and cellular function. Expert opinion: Targeting PPIs is still a challenging approach in drug development and relatively few small molecules have reached clinical development. Potential candidates should be assessed and optimized by properly using the multiple assay systems to develop ideal small molecule drugs. Although there remain some barriers to be overcome, small molecule inhibitors of PPIs are fascinating and first-in-class as therapeutic agents to treat various diseases.

UR - http://www.scopus.com/inward/record.url?scp=85013225906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013225906&partnerID=8YFLogxK

U2 - 10.1080/17460441.2017.1280456

DO - 10.1080/17460441.2017.1280456

M3 - Review article

VL - 12

SP - 293

EP - 303

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 3

ER -